Disease relevance of Lobenzarit

• However, at a concentration of 0.05 mM Lobenzarit did not protect anymore against the paracetamol toxicity, When added to the hepatocytes 1 h and 2 h before paracetamol, 0.05 and 0.2 and 0.3 mM concentrations of lobenzarit did not protect against the cytotoxicity induced by paracetamol either [1].
• Effects of lobenzarit on murine acute viral myocarditis [2].
• MRL/1 mice, which are genetically prone to development of autoimmune disease, were given auranofin or lobenzarit by gavage for 15 weeks, starting at 6 weeks of age [3].
• The gold compound auranofin and lobenzarit (CCA) were compared in regard to effects on development of an autoimmune-like disease in MRL/1 mice, which normally develop elevated levels of serum anti-DNA antibodies and rheumatoid factor as well as joint lesions similar to those seen in patients with rheumatoid arthritis [3].
• Basal bone resorption was inhibited by immunosuppressant cyclosporin A or mizoribine, while immunomodulators lobenzarit and traxanox failed to inhibit basal bone resorption [4].

High impact information on Lobenzarit

• Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug [5].
• The protective effects of lobenzarit, an antioxidative agent and antirheumatic drug, on the cytotoxicity of paracetamol in rat hepatocytes were studied, as well as the inhibitory effects of lobenzarit on cytochrome P-450s and glutathione S-transferases (GSTs) in rat liver [1].
• At concentrations of lobenzarit of 0.2 and 0.3 mM, added 30 min before paracetamol, the drug prevented paracetamol-induced leakage of lactate dehydrogenase (LDH) almost completely and lipid peroxidation (LPO) and depletion of glutathione (GSH) substantially and also the formation of the 3-glutathionyl conjugate of paracetamol [1].
• High-performance liquid chromatographic (HPLC) determination of lobenzarit in plasma and its application to a bioavailability study in beagle dogs [6].
• A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis [7].

Biological context of Lobenzarit

• Regulation of in vitro anti-DNA antibody production by a novel disease modifying anti-rheumatic drug, Lobenzarit [8].

Anatomical context of Lobenzarit

• Lobenzarit (CCA) is a newly developed immunomodulating drug that has been demonstrated to enhance suppressor T-cell number and function [2].
• Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production [9].

Associations of Lobenzarit with other chemical compounds

• A single dose of either cyclosporin-A (CsA) or lobenzarit (CCA) given with an arthrogenic adjuvant completely prevented expression of experimental adjuvant arthritis in rats [9].

Gene context of Lobenzarit

• Treatment of systemic lupus erythematosus with lobenzarit: an open clinical trial [10].

Analytical, diagnostic and therapeutic context of Lobenzarit

• A method for the quantitative determination of lobenzarit (2-[(2-carboxyphenyl)amino]-4-chlorobenzoic acid) in dog plasma by high-performance liquid chromatography with UV detection (308 nm) is described [6].
• The islet survival time in lobenzarit-treated (23.5 +/- 8.0 days) and OK-432-treated (25.3 +/- 13.4 days) groups was not longer than that (21.6 +/- 9.4 days) of the control group [11].

References